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Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system and a leading
cause of neurological disability. The complex immunopathology and variable disease course of multiple
sclerosishavelimitedeffectivetreatmentofallpatients.Alteringthemetabolismofimmunecellsmaybean
attractivestrategytomodifytheirfunctionduringautoimmunity.Weexaminedtheeffectofinhibitingfatty
acid metabolism in experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple
sclerosis. Mice treated with an inhibitor of carnitine palmitoyltransferase 1 (CPT-1), the rate-limiting
enzyme in the beta-oxidation of fatty acids, showed a reduction in disease severity as well as less
inflammation and demyelination. Inhibition of CPT-1 in encephalitogenic T-cells resulted in increased
apoptosisandreducedinflammatorycytokineproduction.Theseresultssuggestthatdisruptionoffattyacid
metabolism promotes downregulation of inflammation in the CNS and that this metabolic pathway is a
potential therapeutic target for multiple sclerosis.
T
he neurological disease multiple sclerosis (MS) results in significant disability in affected patients. The
pathological hallmarks of MS include infiltration of T cells and macrophages into the CNS, microglial
activation, loss of myelin, and disruption of motor, sensory, and cognitive function
1,2,3,4. Although new
therapiestargetingtheimmuneresponsehaverecentlybeenapprovedorareinclinicaltrials,thesenewtherapies
have significant side effects such as increased risk of opportunistic infections
5. Therefore, therapies are needed
that specifically target the inflammatory response in the CNS without global immune impression.
Energyproductiontomeetthedemandsofcellularfunctionisprovidedbymultiplemetabolicpathwayswhich
usesubstratessuchasglucose(glycolysis)orfattyacids(beta-oxidation)toproduceATP
6.Beta-oxidationoffatty
acidsoccursinthemitochondriawhichnecessitatestheimportationoffattyacylgroupsfromthecytosolthrough
the outer and inner mitochondrial membranes
7. However, the mitochondrial membrane is impermeable to
activated acyl-CoA molecules. Therefore, these molecules must be shuttled through the outer membrane via
their conjugation to the quaternary ammonium compound, carnitine, catalyzed by the enzyme CPT-1. In this
reaction the acyl group from CoA is transferred to carnitine enabling the importation of acylcarnitines through
the outer mitochondria membrane. Subsequently, acylcarnitines are transported through the mitochondrial
matrix and converted back to acyl-CoA molecules by a translocase and CPT-2. The conversion of acyl-CoA to
acylcarnitine by CPT-1 is the rate limiting step of beta-oxidation and is regulated by the cellular energy status of
the cell through the production of its endogenous inhibitor malonyl-CoA; therefore, this reaction serves as an
important regulator of cell metabolism
7,8.
Severalstudiesindicatearoleforfattyacidoxidationinsupportingimmunecellfunction.Itwasrecentlyshown
thatTcellsundergoingmetabolicstresssuchasduringthetransitionfromeffectortomemoryTcells,alsoswitch
from primarily using glucose as an energy source to relying on fatty acids
9. Furthermore, T cells that induce graft
vs. host disease (GvHD) show increased levels of acylcarnitine species and a metabolic switch to mitochondrial
fatty acid metabolism
10. In humans, peripheral blood mononuclear cells isolated from patients with infection
show increased levels of acylcarnitines
11, indicating that immune-cell activation could increase the use of fatty
acids for metabolic fuel.
Wesoughttoexaminetheroleofbeta-oxidationduringexperimentalautoimmuneencephalomyelitisbyusing
ethyl 2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate (etomoxir), an irreversible inhibitor of CPT-1. We
describe a role for beta-oxidation in promoting CNS inflammation and regulating encephalitogenic T cell
responses.
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The normal CNS relies primarily on glucose as a major energy
source. Although astrocytes express proteins involved in beta-
oxidation, they do not utilize fatty acids as a major energy source
in nonpathological conditions
12,13. In contrast, under conditions
of metabolic stress such as rapid proliferation, immune cells have
the ability to utilize alternative substrates such as fatty acids
10,14.
However, it is currently unknown whether inflammatory cells
infiltrating intothecentralnervoussystemcontinuetouseglycolysis
or are able to utilize alternate metabolic programs such as fatty acid
oxidation to generate ATP.
Theuseoffattyacidsassubstratestofuelenergyproductionbegins
with their importation into the mitochondria via conjugation to
carnitine by the enzyme CPT-1 and this is the rate-limiting step of
beta-oxidation (Fig. 1). Therefore, we sought to examine the contri-
bution of fatty acid oxidation to the inflammatory response in the
CNS by treating mice with the CPT-1 inhibitor, etomoxir.
Modulators of fatty acid metabolism such as etomoxir have recently
been tested in human phase II clinical trials for congestive heart
failure,andpreclinical evidence alsosuggeststhattheymay beuseful
in the treatment of psoriasis
15,16. EAE was induced with a peptide
from myelin oligodendrocyte glycoprotein (MOG35–55) and mice
were administered etomoxir (15 mg/kg i.p.) or vehicle after disease
priming.Vehicle-treatedmiceshowedascendingparalysisbeginning
at approximately day 10, with hind-limb paralysis evident by day 20.
However, mice that received two doses of etomoxir displayed no or
milddiseasesymptomsthroughoutthesametimecourse(Fig.2aand
SupplementaryMovies1–5).CFA-immunizedcontrolsdisplayedno
disease, and etomoxir treatment of CFA controls did not alter this
phenotype (Supplementary Fig. S1 online).
Next we examined the CNS pathology in vehicle-treated and eto-
moxir-treated mice. To identify lesion-associated CD4
1 T cells and
CD11b
1 macrophages/microglial cells, immunohistochemistry was
performed on spinal cords and the extent to which etomoxir treat-
ment decreased the inflammatory response in EAE was determined.
EAE mice that did not receive the drug displayed robust infiltration
ofinflammatorycellsintothewhitematterregionsofthespinalcord.
In contrast, etomoxir-treated mice displayed a reduced immune cell
infiltrationintheCNSwithfewmacrophages,activatedmicroglia,or
T cells present (Fig. 2b–i and Supplementary Fig. S2 online).
Etomoxir-treated mice displayed less severe inflammation in the
spinalcordandthiscoincidedwithareductioninclinicalsymptoms.
Therefore, we examined whether the improved clinical course
resulted in less myelin damage in the CNS. Spinal cords from eto-
moxir or vehicle-treated mice were stained for myelin basic protein
and the extent of demyelination was compared (Fig. 3). In vehicle-
treatedmice,areasofmyelinlosscoincidedwithregionsofincreased
cellularity (Fig. 3a–c). In contrast, etomoxir-treated mice had intact
myelin sheaths suggesting that a reduction in inflammation pre-
vented myelin destruction (Fig. 3d–f).
Etomoxirreducedinflammation anddemyelinationintheCNSof
treated mice; therefore, we investigated whether inhibition of beta-
oxidation altered the phenotype of myelin-specific T cells. The effect
of etomoxir on T cell cytokine production and apoptosis was exam-
ined under conditions that either favored glycolysis, or reduced
glucose conditions to induce metabolic stress to favor fatty acid
metabolism. Encephalitogenic, MOG-specific T cells were cultured
in medium containing high or low concentrations of glucose, and
cytokine production was measured in the presence or absence of
etomoxir. MOG-specific T-cells cultured in IL-12 exhibit a T-helper
1 (Th1) phenotype characterized by secretion of interferon-gamma
(IFN-c). Under high glucose culture conditions, T cells stimulated
withMOG35–55peptideproducedhighlevelsofIFN-candlittleIL-4,
consistent with a Th1 phenotype exhibited by these cells
17. Etomoxir
treatment did not alter this profile, and no significant difference in
IFN-c production was seen in the presence or absence of drug
(Fig.4a).Incontrast, Tcellsculturedinlowglucose mediumshowed
a significant reduction in IFN-c production in the presence of
etomoxir, without concomitant production of the Th2-associated
cytokine IL-4 (Fig. 4a). The fact that encephalitogenic T-cells are
not skewed toward a Th2 phenotype indicates that the anti-
inflammatory effect of etomoxir is on Th1-associated functions of
the T-cells, rather than off-target effects modulating T helper cell
differentiation. Although MOG-specific T cells were cultured under
conditions that skewed the cells to a Th1 phenotype, IL-17 produc-
tion was also measured after culturing the cells in high and low
glucose medium with or without etomoxir (Supplementary Fig. S3
online). Very low levels of IL-17 were detected in high glucose con-
ditions as expected; however, interestingly no IL-17 production was
detected when cells were cultured in low glucose. This data is con-
sistentwithapreviousreportthatindicatesthatTh17cellsrelyonthe
glycolytic pathway to promote their differentiation
18.
We then examined whether etomoxir decreased inflammation by
promotingapoptosisinactivatedTcells.Recently,ithasbeen shown
that leukemia cells undergo a metabolic switch from glycolysis to
fattyacidoxidationandthatinhibitionofthispathwaywithetomoxir
Figure 1 | Importation of Fatty Acids into the Mitochondria. The first step in the beta-oxidation offatty acids is the transfer of acyl groupsfrom CoA to
carnitine due to the inability of acyl-CoA molecules to cross the mitochondrial membrane. Carnitine palmitoyltransferase 1 (CPT 1), located on the outer
mitochondrialmembrane,transferstheacylgroupfromCoAtocarnitine.Thisistheratelimitingstepinbeta-oxidation.Acylcarnitineandfreecarnitineare
subsequentlyexchangedacrosstheinnermitochondrialmembranebycarnitine-acylcarnitinetranslocase.TheacylgroupisthentransferredbacktoCoAby
carnitine palmitoyltransferase II (CPT-II) on the matrix side of the inner membrane and enters into the beta-oxidation cycle. Etomoxir inhibits CPT I.
www.nature.com/scientificreports
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19. Apoptosis was measured
inMOG-specific Tcells culturedin highor lowglucose medium and
subsequently treated with etomoxir or vehicle. Etomoxir had no
effect on T cells cultured in high glucose, indicating that antigen-
specific T cells retain the ability to perform glycolysis under these
conditions. These results support the hypothesis that glycolysis pre-
dominates in lymphoid organs where glucose is not limited. In con-
trast, there was a significant increase (p , 0.05) in apoptosis in
etomoxir-treatedculturesstimulatedwithantigenunderlowglucose
conditions (Fig. 4b). Furthermore, APO-BrdU labeling of apoptotic
cellsintheCNSshowedincreasedevidenceofcelldeathinetomoxir-
treated mice (Fig. 4c–i). In addition to promoting apoptosis, eto-
moxir may also affect the ability of T cells to proliferate. During
in vitro stimulation of T cells with MOG antigen T cell numbers
increased over the incubation period in high glucose conditions in
the presence of etomoxir, but smaller cell numbers were recovered
from T cells cultured in low glucose in the presence or absence of
etomoxir (data not shown). This indicates that etomoxir may affect
multiple T cell functions during metabolic stress, and future studies
will address whether proliferation or differentiation may be affected.
Togetherthesedataindicatethatetomoxirtreatmentincreasesapop-
tosis of activated, MOG-specific T cells and reduces inflammatory
cytokine production under conditions of competition for glucose as
an energy substrate; a condition that may occur in the lesion micro-
environment within the CNS. The decrease in CNS inflammation
seeninvivomayresultfromtheactionofetomoxironMOG-specific
T cells.
Discussion
This study examines a link between fatty acid oxidation and auto-
immune inflammation in the CNS. Inhibition of CPT-1 resulted
in less severe EAE, reduced inflammation, and demyelination.
Furthermore, inhibition of fatty acid oxidation disrupted encephali-
togenic T cell function. Our study points to a pro-survival role for
beta-oxidation in encephalitogenic T cells. We directly measured
levels of beta-oxidation in encephalitogenic T cells (data not shown)
and are pursuing the effect of etomoxir on this pathway.
Several recent studies have demonstrated an increased use of fatty
acidsubstratesas metabolic fuelto promote inflammatory responses
in psoriasis, graft vs. host disease, and infection
10,11,16. This suggests
that the high metabolic demands of effector functions such as pro-
liferation and cytokine production necessitates the use of multiple
metabolic substrates. Therapies that manipulate upregulated meta-
bolic pathways may prove effective anti-inflammatory therapies,
because their blockage would specifically target cell populations
responsible for promoting autoimmunity.
Figure 2 | CPT-1InhibitionAmelioratesDiseaseActivityDuringEAE. (a)EAEwasinducedwithMOGpeptide.Afterdiseaseinduction,micereceived
2 intraperitoneal injections of etomoxir 15 mg/kg on days 8 and 15 (arrows; (#)) while control mice were injected at the same time points with vehicle
alone ($)( n 54 mice per group; data are representative of three independent experiments). Disease was scored as follows; 05no disease, 15limp tail,
25hind- limb paresis, 35hind-limb paralysis, 45hind/forelimb paralysis, and 55death. Etomoxir-treated-mice show decreased disease compared to
controls(*p,0.05).(b–i)Fluorescenceimmunohistochemistryofinflammatorylesionsinspinalcordsfromvehicle-treated(B–E)andetomoxir-treated
EAE mice (f–i). Sections are stained with FITC-conjugated anti-CD11b to detect macrophages and activated microglia (b, f), and PE-conjugated anti-
CD4 to detect CD4
1 T-cells (c, g), and counterstained with DAPI (d, h). Merged panels are shown in (e) and (i). Scale bar is 50 microns.
www.nature.com/scientificreports
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genic T cells, the anti-inflammatory effectof etomoxir in EAE may be
due to multiple factors. Beta-oxidation may be a pro-survival mech-
anism for antigen-specific or innate inflammatory cells under meta-
bolicstressintheCNSenvironment.Furthermore,itisunknownhow
the balance between glycolysis and fatty oxidation is regulated by
inflammatory cells in the context of inflammation in the central
nervous system. Using 2-[18F]fluoro-2-deoxy-D-glucose and PET
imaging, increased glycolysis was detected in the CNS of mice with
EAE, indicating increased metabolic demands in inflammatory
lesions
20. However,the specificcelltypesresponsible for the increased
uptake of glucose were not determined. Therefore, it is likely that
multiple metabolic pathways are required for energy generation not
only by inflammatory cells, but also resident CNS cells within the
lesions. Conversely, increased acylcarnitine levels similar to those
observed in GVHD or infection
10,11 might be toxic in the CNS.
Acylcarnitines have been postulated to cross the plasma membrane
through an unknown mechanism and previous studies have shown
that accumulation of these species during ischemia in the heart leads
to disruption of membrane integrity and increases in intracellular
calcium
21,22. We cannot rule out a detrimental effect of pathway-
associated substrates on CNS physiology that may be targeted by
etomoxir, and this treatment may exert an anti-inflammatory effect
onmultiplepointsalongthismetabolicpathway.Futurestudiesofthe
roles of different metabolites within the pathway are likely to provide
insights into the complex pathogenesis of CNS inflammation.
In this study we identified the beta-oxidation of fatty acids as a
metabolicpathwayinvolvedinthepathogenesisofEAE.Therapeutic
inhibition of one of the primary enzymes involved in acylcarnitine
catalysis during fatty acid beta-oxidation, CPT-1, reduced disease
symptoms and inflammation in the CNS. These results demonstrate
thatfattyacidmetabolismplaysaroleinsustainingtheinflammatory
response within the CNS and provides a new target for therapeutic
development.
Methods
Mice. All animals were housed according to institutional animal care and use
committee (IACUC) guidelines. Adult female C57BL/6J mice were obtained from
the rodent breeding colony maintained by the Scripps Research Institute (La Jolla,
CA), or purchased from Charles River Labs and maintained at the University of
California, San Diego. EAE was induced as follows; mice received two subcutaneous
injections in the flank of 100 mg of peptide derived from myelin oligodendrocyte
glycoprotein (MOG 35–55) (AnaSpec, San Jose, CA) on days 0 and 7 along with two
intraperitoneal injections of 250 ng pertussis toxin (List Biologicals, Campbell, CA)
on days 0 and 2. Mice were scored according to disease severity 05-no disease,
15limp tail, 25hind-limb paresis, 35hind-limb paralysis, 45hind/forelimb
paralysis, and 55death.
Immunohistochemistry and confocal microscopy. Mice were deeply anesthetized
with halothane and intracardially perfused with ice cold PBS. Following perfusion,
brain and spinal cord were dissected, frozen in OCT mounting medium (Tissue Tek,
Torrance, CA), and 10 mm cryosections were prepared. Inflammatory lesions were
identifiedintissuesectionsusingFITCconjugatedCD11btodetectmacrophagesand
activated microglial cells (eBioscience, San Diego, CA). T-cells were detected using
PE-conjugated anti-CD4. Myelin was stained using SMI-99 (Covance, Emeryville,
CA) followed by Alexa fluor 488 anti-mouse IgG2b secondary (Invitrogen, Carlsbad,
CA). DAPI was used as a counter stain. Images were taken with the Bio-Rad (Zeiss)
Radiance 2100 Rainbow laser scanning confocal microscope (Hercules, CA) or an
Olympus FluoView1000 confocal microscrope (Center Valley, PA) and Image J
analysis software (http://rsb.info.nih.gov/ij/).
Etomoxirtreatment.Etomoxir(Sigma,St. Louis, MO)wasdissolved in sterile water.
Micereceivedintraperitonealinjectionsof15 mg/kginavolumeof100 mlstartingon
day8afterEAEinductionandeitherweeklyoreveryotherdayfortwoweeks.Control
(vehicle-treated) mice received sterile water only.
T cell cultures. C57BL/6 mice were immunized with 200 mg MOG 35-55 peptide
s.c., and 14 days later splenocytes were isolated and cultured at a concentration of
6310
6cells/ml inDMEMcontaininghigh (4.5 g/L)orlow(1 g/L)glucose, 10%FBS
50 mg/ml MOG peptide, and 25 ng/ml IL-12 (R&D systems, Minneapolis, MN) in
the presence of vehicle or 100 mM etomoxir. 72 hours later cells were harvested for
APO-BrdU staining and supernatants collected for IL-4, IL-17 and IFN-c ELISA.
APO-BrdU staining. Apoptosis was detected in MOG-stimulated T cells using the
APO-BrdU kit (Invitrogen, Carlsbad, CA) according to manufacturer’s instructions.
Briefly, cells were fixed in 1% paraformaldehyde followed by incubation in 70%
ethanol at 220uC for 18 hours. DNA was labeled with BrdU for 60 minutes at 37uC
followed by detection with Alexa fluor 488-labeled anti-BrdU (Invitrogen, Carlsbad,
CA) and counterstained with PI/Rnase A staining buffer. Samples were analyzed at
the UCSD Center for AIDS Research flow cytometry core facility. Tissue sections
werefixedin4%formaldehyde, washedinPBS,andpermeabilizedwithproteinaseK.
SectionswerelabeledtheBrdUfor1.5 hoursat37uCandlabelingdetectedwithAlexa
Fluor 488 anti-BrdU antibody followed by counterstaining with DAPI. Slides were
mounted in aquamount and imaged as previously described.
Figure 3 | Demyelination is Reduced by Etomoxir Treatment during EAE. Fluorescent immunohistochemistry for myelin basic protein in the spinal
cordsofvehicle-treated(a–c)oretomoxir-treated(d–f)mice.Prominentareasofmyelinpallorareseeninvehicletreatedmice(a)thatcoincidewithareas
of increased cellularity (b). Merged panel is shown in C. Spinal cords from etomoxir-treated mice show intact myelin (d) along with decreased cellular
infiltration (e). Merge of myelin staining and DAPI is shown in F. Magnification is 200x and scale bar is 50 microns.
www.nature.com/scientificreports
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bars)andIFN-c(greybars)byMOG-stimulatedsplenocytesculturedunderhighorlowglucoseconditionsinthepresenceofetomoxirorvehicle.Datais
representedasmean6S.D.*p,0.05.(b)APO-BrdUlabelingofcellapoptosisinMOG-stimulatedTcellsculturedinlow(greybars)orhigh(blackbars)
glucose medium. Positive and negative control cells are a lymphoma cell line supplied by the manufacturer. Data is representative of three independent
experimentsandplottedasmean6S.D.,*p,0.05. Fluorescence immunohistochemistry forDAPI(c),Apo-BrdU(d), andmerge (e)inthe spinalcord
ofavehicle-treated mouseandDAPI (f),APO-BrdU(g)andmerge(h)inthespinal cordofan etomoxir-treated mouse.Increasedapoptosis isseen after
etomoxirtreatment.Scalebaris50micronsandmagnificationis200x.(I)QuantitationofApo-BrdUfluorescenceinspinalcordsofvehicle-treated(grey
bars) and etomoxir-treated (black bars) mice. Data is expressed as area of Apo-BrdU fluorescence/total spinal cord area (mean 6 S.D.).
www.nature.com/scientificreports
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peptide stimulation and analyzed using IL-4, IFN-c, and IL-17 ELISA kits according
to manufacturer’s instructions. (eBioscience, San Diego, CA).
Statistics.Diseasescoresareexpressedasmeans6standarderrorofthemean(SEM).
Statistical analysis was performed with two-tailed Student’s t tests for unpaired data.
For the animal studies, disease scores were analyzed using the Mann-Whitney U test
(GraphPad Prism), where a p value of ,0.05 was considered as statistically
significant.
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